Washington University School of Medicine

Digital Commons@Becker
2014 Personalized Medicine? Using sequencing
(and other assays) in clinical trials: FDA rules
and regulations

2014 Conferences

2014

Investigational device exemption
E. David Litwack
FDA, Personalized Medicine Staff, Office of In Vitro Diagnostics

Follow this and additional works at: https://digitalcommons.wustl.edu/hrpoconf_personalizedmed_2014

Recommended Citation
Litwack, E. David, "Investigational device exemption" (2014). 2014 Personalized Medicine? Using
sequencing (and other assays) in clinical trials: FDA rules and regulations. Paper 2.
https://digitalcommons.wustl.edu/hrpoconf_personalizedmed_2014/2

This Presentation is brought to you for free and open access by the 2014 Conferences at Digital
Commons@Becker. It has been accepted for inclusion in 2014 Personalized Medicine? Using sequencing (and
other assays) in clinical trials: FDA rules and regulations by an authorized administrator of Digital
Commons@Becker. For more information, please contact vanam@wustl.edu.

Investigational Device Exemption
(IDE)
David Litwack
ernest.litwack@fda.hhs.gov
Personalized Medicine Staff
Office of In Vitro Diagnostics
CDRH/FDA
November 21, 2014

DISCLAIMER
• Thoughts presented here regarding new policy /
regulatory issues are preliminary and do not represent
finalized FDA policy
• FDA cannot comment on specific investigations.

ISSUES
• FDA is seeing more researchers apply
discoveries in the clinic.
• Most academic researchers do not understand
their obligations under the IDE regulation.
• Most academic institutions do not provide
adequate regulatory support.

In Vitro Diagnostics (IVDs)
•

In vitro diagnostic devices include “…those reagents, instruments, and
systems intended for use in the diagnosis of disease or other
conditions, including a determination of the state of health, in order to
cure, mitigate, treat, or prevent disease or its sequelae. Such products
are intended for use in the collection, preparation, and examination of
specimens taken from the human body. These products are devices as
defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act ”
(21 CFR 809.3)

•

Intended use: How will the device will be used in the therapeutic
product trial? Encompasses:
–
–
–
–
–
–

Analyte to be detected
Type of result (quantitative, semi-quantitative, qualitative)
Specimen type(s)
Disease to be screened, monitored, treated, or diagnosed
Target subject population
etc.

Intended Use
What assay measures, how to use results
I ntended
P opulation

Analyte

I ndication
For Use

Example:

MammaPrint® is a qualitative in vitro diagnostic test service, performed in a single
laboratory, using the gene ex pression profile of fresh frozen breast cancer
tissue samples to assess a patients' risk for distant metastasis.
The test is performed for breast cancer patients who are less than 61 years old,
with Stage I or Stage II disease, with tumor size <= 5.0 cm and who are lymph
node negative. The MammaPrint® result is indicated for use by physicians as
a prognostic m arker only, along w ith other clinicopathological factors.

Types of studies depend on IU claims;
Less dependent on the technology or assay format

Things that are or can be medical
devices include:
• Instrumentation
• In vitro diagnostic kits
• Reagents used for laboratory
testing
• Some apps
• Software
• Algorithms
Medical devices are subject to regulatory requirements
even though they may only be investigational.

Some common misconceptions:
• It is not a test, it is a process.
• It is not an IVD if it is in the research and development
stage.
• It is not an IVD if I don’t plan to market the test.
• The IDE regulation does not apply if I don’t plan to
market the test.
• I have CLIA certification, so I don’t need to worry about
the IDE regulation.
• I can never generate enough data to submit an IDE.

PRECLINICAL
RESEARCH

CLINICAL
INVESTIGATION

COMMERCIAL
SALES

Research lab

Clinical lab

“Manufacturing”

CLIA
IDE
Protect human subjects

PMA or 510k
Assure safety and
effectiveness

What is an investigation?
• Investigation means a clinical investigation or research
involving one or more subjects to determine the safety or
effectiveness of a device.

Definition of “Subject” for Investigations
• Subject means a human who participates in an
investigation, either as an individual on whom or
on whose specimen an investigational device is
used or as a control. A subject may be in normal
health or may have a medical condition or
disease.

What is an Investigational Device?
• Investigational device means a device…that is the object of
an investigation.
• An investigational IVD is not legally marketed for the intended
use or indication for use identified in that study, whether or not
it has been previously cleared or approved for a separate
intended use.
• Important to distinguish from off-label use or practice of
medicine.
• Investigational use requires an exemption from premarket
approval requirements for new drugs and devices.

IVDs: Companion Diagnostics
• Companion diagnostics are IVDs
• An IVD companion diagnostic device is an in vitro diagnostic device
that provides information that is essential for the safe and effective
use of a corresponding therapeutic product.
– Note: it is important to recognize, for example, that when a validated prognostic
test is used to select patients for treatment, the ability to select patients who are
expected to benefit from the treatment is an investigational use for which the test
has not been validated until the investigational therapeutic product has
demonstrated safety and efficacy in the test-selected population.

• Drugs and their companion tests refer to each other in their labels.
• Draft guidance. In vitro companion diagnostic devices.
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/
GuidanceDocuments/ucm262292.htm

MARKER USED TO SELECT TREATMENT
Test result influences treatment.
investigational IVD

marker positive

investigational
treatment

placebo or
comparator

marker negative

excluded from trial
and/or receive SOC

MARKER USED FOR STRATIFICATION
Test result does not influence treatment.

investigational IVD

marker positive

investigational
treatment

placebo or
comparator

marker negative

investigational
treatment

placebo or
comparator

Other trial designs
• Adaptive
• Basket trials

IDE Regulation (21 CFR 812)
• “…purpose…is to encourage, to the extent consistent with the
protection of public health and safety and with ethical
standards, the discovery and development of useful devices
intended for human use, and to that end to maintain optimum
freedom for scientific investigators in their pursuit of this purpose.”
• An IDE is a regulatory submission that permits clinical
investigation of devices/IVDs.
• An approved IDE permits a device to be shipped lawfully for the
purpose of conducting investigations of the device without
complying with other requirements of the Food, Drug, and
Cosmetic Act (Act) that would apply to devices in commercial
distribution.
• Focused on risk
• Delegated responsibilities

IDE approval aims to ensure that:
• Risks are outweighed by anticipated benefits to
subjects and importance of knowledge to be
gained.
• Informed consent is adequate.
• Investigation is scientifically sound.

All Device Investigations
Studies Subject to the
IDE Regulation

Studies Exempt
from the IDE
Regulation

Significant Risk

Non-Significant Risk

Full Requirements

Abbreviated
Requirements

IDE: A Risk-Based Approach to IVD
Regulation
• IDE requirements depend on the risk of the test use to
study subjects in the investigation.
• For IVD tests, it is important to think about the risks
associated with erroneous test results. What would
happen if the test results are wrong?
– False positive or false negative results mean that a patient may
be diverted from therapeutic options which may be more
beneficial to them.
– Patients may be subject to adverse events from the
investigational trial when they are not intended to be the subject
of the investigation.
19

IDE Exempt
• 812.2(c)(3): A diagnostic device [is exempt], if the sponsor complies
with applicable requirements in 809.10(c) [labeling] and if the
testing:
– (i) Is noninvasive,
– (ii) Does not require an invasive sampling procedure that presents
significant risk,
– (iii) Does not by design or intention introduce energy into a subject, and
– (iv) Is not used as a diagnostic procedure without confirmation of the
diagnosis by another, medically established diagnostic product or
procedure.

• Example: Use of an in vitro diagnostic in a retrospective study of
accrued specimens (without return of results).
• Depends on interpretation of “medically established”.

Nonsignificant risk (NSR)
• Does not meet the definition of significant risk (SR) in 812.3(m).
• Abbreviated requirements:
– Labeling (812.5)
– IRB approval
– Informed consent (part 50)
– Monitoring (812.46)
– Records (812.140) and reporting (812.150) (sponsor and
investigator)
– Prohibition against promotion and other practices (812.7.)
• No IDE application to the FDA required. Meeting the abbreviated
requirements (including IRB approval!) means that you have an
approved application for an IDE.
• Example: Use of an investigational IVD test to stratify patients for
treatment in a clinical trial.

Significant Risk (SR)
• Significant risk device (812.3(m)) means an investigational device
that:
– 1) Is intended as an implant and presents a potential for serious
risk to the health, safety, or welfare of a subject;
– (2) Is purported or represented to be for a use in supporting or
sustaining human life and presents a potential for serious risk to
the health, safety, or welfare of a subject;
– (3) Is for a use of substantial importance in diagnosing, curing,
mitigating, or treating disease, or otherwise preventing
impairment of human health and presents a potential for serious
risk to the health, safety, or welfare of a subject; or
– (4) Otherwise presents a potential for serious risk to the health,
safety, or welfare of a subject.
• Example: Use of an investigational in vitro diagnostic test to select
patients for a clinical trial.

BALANCED APPROACH TO IVD RISK
Context and effect of an incorrect test result
Cancer is a
serious disease.
Any effect on a
treatment decision
arising from IVD
use poses
significant risk.
•
•
•
•
•
•

More Risk

Accrual by test result
Rx assignment
Safety signal for Rx
Convenience biomarker
Weak/conflicting info on
biomarker effect
Invasive sampling

Less Risk

•
•
•
•
•
•

Cancer is a
serious disease.
Large and unmet
medical need
makes any IVD
risk minor.

All-comers accrual
Stratification
No “known effective” Rx
Targeted biomarker
Strong biomarker effect
known
Non-invasive sampling

Assessing Risk
1. Will use of the investigational test results lead to some trial subjects
foregoing or delaying a treatment that is known to be effective?
2. Will use of the investigational test results expose trial subjects to
safety risks (e.g., adverse events from the experimental therapy)
that (in some “net” sense) exceed the risks encountered with
control therapies or non-trial standard of care?
3. Is it likely, based on a priori information about the investigational
therapy, that incorrect test results would degrade the safety or
efficacy of subjects’ treatment?
4. Does specimen acquisition, done for investigational testing and
outside the standard of care, require an invasive sampling
procedure that presents significant risk?

Risk in Investigations Using Genetic
Testing
• What are the clinical indications for testing?
• Are the results confirmed by an acceptable technique? What
is an acceptable technique?
• Are results returned?
• Will results be placed in the medical record?
• How are results communicated to the treating physician?
• What are the risks of an incorrect test result?
– What clinical actions might be taken based on test results?
– How urgent are the results?

Some Features with Lesser Relevance for
IVD Risk Determination
• Size of trial
• Access to “other trials”
• Clinical trial phase

Risk in Ongoing Trials
• Risk can change during the course of a trial.
– Adaptive trials
– Protocol changes
– New information (DSMB review)
• If IVD use becomes SR in the middle of a trial, an IDE is
required.
• Ongoing surveillance is recommended.

Example 1
Researchers have identified a biomarker that they hypothesize will
predict response to a new drug for colorectal cancer. They develop
an IVD to detect the biomarker, and design a clinical trial in which
only those patients that are positive for the biomarker will receive
the drug. Other inclusion criteria specify that the patients have
exhausted all other lines of therapy.
– What is the risk of the use of IVD in the trial?
– If an earlier trial of the drug identified potentially serious or lifethreatening toxicities, would your risk assessment change?

Example 1
– Initial decision: NSR. Although the IVD is used for
selection, there are no known effective therapies
remaining for patients. Therefore, false results do not pose
added risk to patients.
– Modified decision: SR. Although there are no known
effective therapies remaining, side effects from the drug
may unreasonably degrade quality of life or lead to death
earlier than would be predicted from the normal course of
the disease. False positive patients would be exposed to
these risks without any reasonable expectation of benefit.

Example 2
Researchers have developed a test to detect a biomarker in bone marrow,
and design a clinical trial to use the IVD to select patients with pancreatic
cancer to receive a drug that is approved for use in prostate cancer. To
enter the trial, patients must have additional bone marrow biopsies, and
have not received any prior lines of therapy. The toxicities of the drug are
well-understood and can be mitigated with appropriate monitoring.
– What is the risk of the use of IVD in the trial?
– What if an earlier trial suggested that marker-positive patients with
pancreatic cancer could respond to the new drug?

Example 2
– Initial decision: SR. The IVD is used for selection. False results will
divert patients from standard of care or known effective therapies.
– Modified decision: NSR. Given preliminary indications that the
biomarker predicts response to the drug, test-positive patients have a
reasonable expectation of benefit. False results can be mitigated by
monitoring. While extra bone marrow biopsies are invasive, they may
not pose high enough risk to qualify the study as significant risk.
– In real life, this scenario should be discussed with FDA.

Delegated Responsibilities and Risk Determination
•

Sponsor makes initial determination and
presents to IRB

•

IRB reviews determination; agrees or modifies

•

FDA can help; FDA determination is final

Some Recommended Questions for IRBs
1. Are one or more IVD devices being used in this study to select patients for
treatment?
2. Is the device investigational?
a. Has the device been cleared or approved by the FDA?
b. If the IVD has been cleared or approved, is it being put to a new use in
the trial?
3. What are the risks of IVD use in the study?
a. Does specimen collection present a risk?
b. What are the risks of inaccurate results?
i. Is the IVD used for enrollment or assignment to an arm?
ii. Will the IVD be used for patient monitoring or adjusting dosage?
iii. Are the benefits of treatment greater than the risks of an inaccurate
IVD result?
4. Will results from the IVD device be supported by use of an independent
confirmatory test?
5. Does the informed consent cover the use of the investigational IVD?

FDA Policy for CDx Trials
• SR IVD: An IDE is required for an investigation even if there is an
IND for use of the drug, or if the drug is IND exempt.
• NSR IVD: An IDE is not required, and cannot be accepted for
review.
– The trial still has to comply with the abbreviated requirements.
– Some information on the test may be requested in the IND.
– A presubmission with CDRH is recommended.
• A trial may not proceed until it has received IND and/or IDE approval
AND IRB approval.

Common Problems
• Failure to recognize that the biomarker test is an investigational
medical device.
• Expectation that compliance with IND regulation is sufficient to
satisfy requirements under the IDE regulation.
• Risk misdetermination. If the IRB agrees the device is NSR,
FDA will never see a submission, and will be unaware of the
trial.
• Change in risk during course of trial.

Presubmission Process
– You can meet with the FDA for nonbinding discussions and
advice:
• before conducting studies, including clinical trials
• before submitting a marketing application
– This is an opportunity to address new scientific and regulatory
issues.
– Particularly important when developing new technologies.
– The earlier the better!
– Draft Guidance on the presubmission process
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidan
ce/GuidanceDocuments/ucm310375.htm.

Resources
• Guidance
– IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of
Research Sites, and the Determination of Whether an IND/IDE is Needed.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM328855.pdf
– FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations.
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guid
anceDocuments/UCM279107.pdf
– Significant Risk and Nonsignificant Risk Medical Device Studies.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126418.pdf
– Others at www.fda.gov

• Device Advice
– http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/default.htm

• CDRH Learn (including information about sponsor responsibilities,
investigator responsibilities, IRBs, and the Bioresearch Monitoring
Program)
– http://www.fda.gov/Training/CDRHLearn/default.htm

Other FDA efforts
• Educational –
– Conferences
– Discussion with IRBs, academic investigators,
and institutions

• Work with NIH to disseminate information
early in the granting process

